VACATURE: QC Technician

Ter uitbreiding van onze Quality Control afdeling zoeken wij per direct kandidaten met een HLO opleiding in biochemie of gelijkwaardig (klinisch, medisch of biologisch) voor de functie van QC Technician. Maak jij het verschil en ben je toe aan een nieuwe uitdaging? Solliciteer nu op deze vacature en sluit je aan bij ons team van professionals! Future Diagnostics […]

Free 25OH Vitamin D or Total 25OH Vitamin D?

Currently, Free T4 (thyroid hormone) measurements are well established in clinical diagnostics. Free T4 measurements, which reflect both total T4 levels and binding protein capacity, have become the recognized standard for determining thyroid status in conjunction with a TSH measurement. Similarly, in several conditions such as pregnancy, renal disease or liver disease the level of Vitamin […]

Kick-start Assay Development Future Diagnostics

Why Pre-Feasibility Studies are important

Future Diagnostics performs pre-feasibility studies for third parties within the global medical technology and IVD market. These pre-feasibility studies are performed on different types of raw materials or assays. It can also be done on a variety of technologies and analyzers, both immunologically or molecular based. Have a look at our presentation on Slideshare

Team Future Diagnostics

Future Diagnostics’ 20th Anniversary

This week we are proud to be celebrating the 20th Anniversary of Future Diagnostics. We take this opportunity to thank all our employees, customers, partners and other stakeholders for their loyalty and helping us succeed.

MIDS logo

Zenosense, Inc: MML Engages Future Diagnostics for Assay Consulting Services

VALENCIA, SPAIN, March 2017: Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain […]

TK210 ELISA Reagents

AroCell’s partnership with Future Diagnostics

“Biological materials have a mind of their own” AroCell’s research and development staff members started a valuable collaboration with Future Diagnostics in the Netherlands in 2011, for the development of the TK 210 ELISA test throughout all these different phases. Collaboration between AroCell team members and this extended contract assay development organization has led to […]

Point-of-Care Test Development Services

Point-of-Care Test Development, It’s an Art

According to IVD companies, the market for near-patient testing is growing significantly. Diagnosis by Point-of-Care testing accelerates patient care decision-making and fast-tracks the time to initiate treatment. Because of the complexity, regulatory guidelines and the complicated set-up of POC platforms the growth potential is limited. Talking to our scientists, I learned about the complex decisions that have to […]

Future Diagnostics and DIAsource received a grant of 1.4m Euro to develop a CE marked unique Free Vitamin D assay for the IVD market

Future Diagnostics and DIAsource received a grant of 1.4m Euro from Eurostars (European Commission) Grant supports demonstration clinical utility and obtaining CE marking of the world’s first assay to measure Free Vitamin D Future Diagnostics Solutions (Wijchen, The Netherlands) and DIAsource Immunoassays SA, part of the Anteo Group (ASX: ADO), are pleased to announce that […]

Free or Total 25OH Vitamin D

Free 25OH Vitamin D seems to be a better marker of Vitamin D status than Total 25OH Vitamin D. Learn more about this topic at: 6th International Conference on Vitamin D deficiency Nutrition and Human Health in Abu Dhabi, United Arab Emirates from March 9th to 10th, 2017 This year’s meeting will focus on the […]